Merrimack To Announce Phase 3 Napoli-1 Study Results Orally At ESMO GI

(RTTNews) - Merrimack Pharmaceuticals, Inc. (MACK) Tuesday said it will announce the results of its final stage Napoli-1 study for MM-398 in an oral presentation at the European Society for Medical Oncology 16th World Congress on Gastrointestinal Cancer, which is to be held from June 25 to 28 at the International Convention Center of Barcelona in Spain.

The presentation will include additional efficacy and safety data from the three arm study of MM-398, a nanoliposomal irinotecan, in patients with metastatic pancreatic cancer who have received prior gemcitabine-based therapy.